These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35163067)

  • 1. Somatostatin Receptor Splicing Variant
    Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Peel A; Blanco-Acevedo C; Solivera J; Ibáñez-Costa A; Gahete MD; Castaño JP; Luque RM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
    Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
    FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types.
    Del Rio-Moreno M; Alors-Perez E; Borges de Souza P; Prados-Gonzalez ME; CastaÑo JP; Luque RM; Gahete MD
    Transl Res; 2019 Sep; 211():147-160. PubMed ID: 30904441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.
    Durán-Prado M; Gahete MD; Hergueta-Redondo M; Martínez-Fuentes AJ; Córdoba-Chacón J; Palacios J; Gracia-Navarro F; Moreno-Bueno G; Malagón MM; Luque RM; Castaño JP
    Oncogene; 2012 Apr; 31(16):2049-61. PubMed ID: 21927030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
    Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
    Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
    Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
    Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.
    Gahete MD; Rincón-Fernández D; Durán-Prado M; Hergueta-Redondo M; Ibáñez-Costa A; Rojo-Sebastián A; Gracia-Navarro F; Culler MD; Casanovas O; Moreno-Bueno G; Luque RM; Castaño JP
    Oncotarget; 2016 Sep; 7(37):60110-60122. PubMed ID: 27507050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
    Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
    J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Gonçalves CS; Vieira de Castro J; Pojo M; Martins EP; Queirós S; Chautard E; Taipa R; Pires MM; Pinto AA; Pardal F; Custódia C; Faria CC; Clara C; Reis RM; Sousa N; Costa BM
    Theranostics; 2018; 8(17):4805-4823. PubMed ID: 30279739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells.
    Molè D; Gentilin E; Ibañez-Costa A; Gagliano T; Gahete MD; Tagliati F; Rossi R; Pelizzo MR; Pansini G; Luque RM; Castaño JP; degli Uberti E; Zatelli MC
    Endocrine; 2015 Nov; 50(2):442-52. PubMed ID: 25854304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.
    Puig-Domingo M; Luque RM; Reverter JL; López-Sánchez LM; Gahete MD; Culler MD; Díaz-Soto G; Lomeña F; Squarcia M; Mate JL; Mora M; Fernández-Cruz L; Vidal O; Alastrué A; Balibrea J; Halperin I; Mauricio D; Castaño JP
    PLoS One; 2014; 9(1):e85527. PubMed ID: 24465589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma.
    Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO
    Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.
    Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V
    J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFLAM correlates with cell proliferation, migration, invasion and poor prognosis in glioblastoma.
    Chen J; Zhang J; Hong L; Zhou Y
    Cancer Biomark; 2019; 24(3):343-350. PubMed ID: 30829611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
    Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
    J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma.
    Se YB; Kim SH; Kim JY; Kim JE; Dho YS; Kim JW; Kim YH; Woo HG; Kim SH; Kang SH; Kim HJ; Kim TM; Lee ST; Choi SH; Park SH; Kim IH; Kim DG; Park CK
    Cancer Res Treat; 2017 Apr; 49(2):387-398. PubMed ID: 27456940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin.
    Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.